Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

 
• By Sten Stovall
  
Sickle cells
Sevuparin is an anti-adhesive drug now in Phase II Trials in "core" SCD countries • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business